Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Keita Masuzawa, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. However, there are no direct comparison data to guide the selection of a thirdgeneration EGFR-TKI for patients with different EGFR mutations. We previously established an in vitro model to estimate the therapeutic windows of EGFR-TKIs by comparing their relative efficacies against cells expressing mutant or wild type EGFRs. The present study used this approach to characterize the efficacy of third-generation EGFR-TKIs and compare them with that of other EGFR-TKIs. Treatment efficacy was examined using human lung cancer-derived cell lines and Ba/F3 cells, which were transduced with clinically relevant mutant EGFRs. Interestingly, mutation-related differences in EGFR-TKI sensitivity were observed. For classic EGFR mutations (exon 19 deletion and L858R, with or without T790M), osimertinib showed lower IC50 values and wider therapeutic windows than nazartinib. For less common EGFR mutations (G719S or L861Q), afatinib showed the lowest IC50 values. For G719S+T790M or L861Q+T790M, the IC50 values of osimertinib and nazartinib were around 100 nM, which was 10- to 100-fold higher than those for classic+T790M mutations. On the contrary, osimertinib and nazartinib showed similar efficacies in cells expressing EGFR exon 20 insertions. The findings highlight the diverse mutation-related sensitivity pattern of EGFR-TKIs. These data may help in the selection of EGFR-TKIs for non-small cell lung cancer patients harboring EGFR mutations.

Original languageEnglish
Pages (from-to)105479-105491
Number of pages13
JournalOncotarget
Volume8
Issue number62
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Epidermal Growth Factor Receptor
Mutation
Inhibitory Concentration 50
osimertinib
Exons
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Lung Neoplasms

Keywords

  • EGFR mutations
  • EGFR tyrosine kinase inhibitors
  • Lung cancer
  • Nazartinib
  • Osimertinib

ASJC Scopus subject areas

  • Oncology

Cite this

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. / Masuzawa, Keita; Yasuda, Hiroyuki; Hamamoto, Junko; Nukaga, Shigenari; Hirano, Toshiyuki; Kawada, Ichiro; Naoki, Katsuhiko; Soejima, Kenzo; Betsuyaku, Tomoko.

In: Oncotarget, Vol. 8, No. 62, 01.01.2017, p. 105479-105491.

Research output: Contribution to journalArticle

Masuzawa, Keita ; Yasuda, Hiroyuki ; Hamamoto, Junko ; Nukaga, Shigenari ; Hirano, Toshiyuki ; Kawada, Ichiro ; Naoki, Katsuhiko ; Soejima, Kenzo ; Betsuyaku, Tomoko. / Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. In: Oncotarget. 2017 ; Vol. 8, No. 62. pp. 105479-105491.
@article{b98b44c3f5e341bda538454de6080136,
title = "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations",
abstract = "Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. However, there are no direct comparison data to guide the selection of a thirdgeneration EGFR-TKI for patients with different EGFR mutations. We previously established an in vitro model to estimate the therapeutic windows of EGFR-TKIs by comparing their relative efficacies against cells expressing mutant or wild type EGFRs. The present study used this approach to characterize the efficacy of third-generation EGFR-TKIs and compare them with that of other EGFR-TKIs. Treatment efficacy was examined using human lung cancer-derived cell lines and Ba/F3 cells, which were transduced with clinically relevant mutant EGFRs. Interestingly, mutation-related differences in EGFR-TKI sensitivity were observed. For classic EGFR mutations (exon 19 deletion and L858R, with or without T790M), osimertinib showed lower IC50 values and wider therapeutic windows than nazartinib. For less common EGFR mutations (G719S or L861Q), afatinib showed the lowest IC50 values. For G719S+T790M or L861Q+T790M, the IC50 values of osimertinib and nazartinib were around 100 nM, which was 10- to 100-fold higher than those for classic+T790M mutations. On the contrary, osimertinib and nazartinib showed similar efficacies in cells expressing EGFR exon 20 insertions. The findings highlight the diverse mutation-related sensitivity pattern of EGFR-TKIs. These data may help in the selection of EGFR-TKIs for non-small cell lung cancer patients harboring EGFR mutations.",
keywords = "EGFR mutations, EGFR tyrosine kinase inhibitors, Lung cancer, Nazartinib, Osimertinib",
author = "Keita Masuzawa and Hiroyuki Yasuda and Junko Hamamoto and Shigenari Nukaga and Toshiyuki Hirano and Ichiro Kawada and Katsuhiko Naoki and Kenzo Soejima and Tomoko Betsuyaku",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22297",
language = "English",
volume = "8",
pages = "105479--105491",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "62",

}

TY - JOUR

T1 - Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

AU - Masuzawa, Keita

AU - Yasuda, Hiroyuki

AU - Hamamoto, Junko

AU - Nukaga, Shigenari

AU - Hirano, Toshiyuki

AU - Kawada, Ichiro

AU - Naoki, Katsuhiko

AU - Soejima, Kenzo

AU - Betsuyaku, Tomoko

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. However, there are no direct comparison data to guide the selection of a thirdgeneration EGFR-TKI for patients with different EGFR mutations. We previously established an in vitro model to estimate the therapeutic windows of EGFR-TKIs by comparing their relative efficacies against cells expressing mutant or wild type EGFRs. The present study used this approach to characterize the efficacy of third-generation EGFR-TKIs and compare them with that of other EGFR-TKIs. Treatment efficacy was examined using human lung cancer-derived cell lines and Ba/F3 cells, which were transduced with clinically relevant mutant EGFRs. Interestingly, mutation-related differences in EGFR-TKI sensitivity were observed. For classic EGFR mutations (exon 19 deletion and L858R, with or without T790M), osimertinib showed lower IC50 values and wider therapeutic windows than nazartinib. For less common EGFR mutations (G719S or L861Q), afatinib showed the lowest IC50 values. For G719S+T790M or L861Q+T790M, the IC50 values of osimertinib and nazartinib were around 100 nM, which was 10- to 100-fold higher than those for classic+T790M mutations. On the contrary, osimertinib and nazartinib showed similar efficacies in cells expressing EGFR exon 20 insertions. The findings highlight the diverse mutation-related sensitivity pattern of EGFR-TKIs. These data may help in the selection of EGFR-TKIs for non-small cell lung cancer patients harboring EGFR mutations.

AB - Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. However, there are no direct comparison data to guide the selection of a thirdgeneration EGFR-TKI for patients with different EGFR mutations. We previously established an in vitro model to estimate the therapeutic windows of EGFR-TKIs by comparing their relative efficacies against cells expressing mutant or wild type EGFRs. The present study used this approach to characterize the efficacy of third-generation EGFR-TKIs and compare them with that of other EGFR-TKIs. Treatment efficacy was examined using human lung cancer-derived cell lines and Ba/F3 cells, which were transduced with clinically relevant mutant EGFRs. Interestingly, mutation-related differences in EGFR-TKI sensitivity were observed. For classic EGFR mutations (exon 19 deletion and L858R, with or without T790M), osimertinib showed lower IC50 values and wider therapeutic windows than nazartinib. For less common EGFR mutations (G719S or L861Q), afatinib showed the lowest IC50 values. For G719S+T790M or L861Q+T790M, the IC50 values of osimertinib and nazartinib were around 100 nM, which was 10- to 100-fold higher than those for classic+T790M mutations. On the contrary, osimertinib and nazartinib showed similar efficacies in cells expressing EGFR exon 20 insertions. The findings highlight the diverse mutation-related sensitivity pattern of EGFR-TKIs. These data may help in the selection of EGFR-TKIs for non-small cell lung cancer patients harboring EGFR mutations.

KW - EGFR mutations

KW - EGFR tyrosine kinase inhibitors

KW - Lung cancer

KW - Nazartinib

KW - Osimertinib

UR - http://www.scopus.com/inward/record.url?scp=85036542241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036542241&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22297

DO - 10.18632/oncotarget.22297

M3 - Article

VL - 8

SP - 105479

EP - 105491

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 62

ER -